Table 1.
Patient demographic and procedure data in patients with hyperemic cutaneous periocular abnormal following intraarterial chemotherapy for retinoblastoma
| Patient no. | Age, months | Drug used | Dose | Cycle seen | Comments |
|---|---|---|---|---|---|
| 1 | 59 | Mel./Topo. | 5mg/1.5mg | 3,5 | - |
| 2 | 12 | Mel. | 5mg | 3 | - |
| 3 | 26 | Mel. | 7.5 mg | 3 | Wedge flow |
| 4 | 6 | Mel. | 3 mg | 1 | - |
| 5 | 9 | Mel. /Topo. | 6 mg/0.4mg | 2 | - |
| 6 | 32 | Mel. | 5 mg | 1 | - |
| 7 | 10 | Mel. | 4 mg | 2 | Wedge flow |
| 8 | 120 | Mel. | 6 mg | 2 | - |
| 9 | 6 | Mel. | 3 | mg 1 | - |
| 10 | 34 | Mel. | 7.5 mg | 3 | Wedge flow |
| 11 | 30 | Mel./Carbo. | 7.5 mg /3.0mg | 3 | Wedge flow |
Mel. = Melphalan, Topo. = Topotecan, Carbo. = Carboplatin